CLEVELAND--(BUSINESS WIRE)--Imalux Corporation (“Imalux”), a medical device company and developer of the Niris™ Imaging System based on Optical Coherence Tomography (“OCT”) technology, today announced the successful closing of its Series C Preferred Shares Offering. Proceeds from the Offering were $5.1 million, including conversion of $2.5 million of bridge financing. Lead investors Early Stage Partners, ElectroSonics Medical, Reservoir Venture Partners, and Symark were joined by more than twenty prior and new investors in the financing.
